ReviewTheScientificWorldJournal2016
Hepatitis C Virus in North Africa: An Emerging Threat.
Review in TheScientificWorldJournal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Systematic review and meta-analysis of HIV, HBV and HCV infection prevalence in Sudan.Virology journal · 2018Pooled it
- The Epidemiology of Hepatitis D Virus in North Africa: A Systematic Review and Meta-Analysis.TheScientificWorldJournal · 2018Pooled it
- HBV and HCV testing outcomes among marginalized communities in Italy, 2019-2024: a prospective study.The Lancet regional health. Europe · 2025Article
- Syndemic geographic patterns of integrated diseases during the Libyan armed conflict; a new aspect for public health care intervention?Frontiers in epidemiology · 2025Article
- Hepatitis C in North Africa: A Comprehensive Review of Epidemiology, Genotypic Diversity, and Hepatocellular Carcinoma.Advances in virology · 2025Review
- Advancing Hepatitis C Elimination in Africa: Insights from Egypt.Hepatic medicine : evidence and research · 2024Review
- Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- Molecular characterization and genotyping of hepatitis C virus from Sudanese end-stage renal disease patients on haemodialysis.BMC infectious diseases · 2022Article
- The epidemiological characterization and geographic distribution of hepatitis D virus infection in Libya.The Pan African medical journal · 2020Article
- An update on hepatitis C virus genotype distribution in Jordan: a 12-year retrospective study from a tertiary care teaching hospital in Amman.BMC infectious diseases · 2019Article
- Spatiotemporal analysis and epidemiological characterization of the human immunodeficiency virus (HIV) in Libya within a twenty five year period: 1993-2017.AIDS research and therapy · 2019Article
- The geographic variation and spatiotemporal distribution of hepatitis C virus infection in Libya: 2007-2016.BMC infectious diseases · 2018Article
- Communicable Diseases in the Mediterranean Region.EJIFCC · 2018Article
- Molecular and epidemiological characterization of HIV-1 subtypes among Libyan patients.BMC research notes · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus is a major public health threat associated with serious clinical consequences worldwide. North Africa is a unique region composed of seven countries that vary considerably in the predisposing factors to microbial diseases both historically and at the present time. The dynamics of HCV in the region are not well documented. The data are both limited and controversial in most of the countries in the region. In North Africa, the epidemiology of HCV is disparate and understanding it has been hampered by regional "epidemiological homogeneity" concepts. As the dynamics of HCV vary from country to country, context-specific research is needed. In this review, we assess studies performed in each country in the general populations as well as among blood donors and groups exposed to the HCV infection. The reported prevalence of HCV ranges from 0.6% to 8.4% in the Maghreb countries and is predominated by genotype 1. In the Nile valley region, it ranges from 2.2% to 18.9% and is dominated by genotype 4. In North African countries, HCV seems to be a serious problem that is driven by different vectors even in different geographical locations within the same country. Efforts should be combined at both the national and regional levels to implement efficient preventive and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.